Table 5 Clinical trials for combination of OV with small-molecule modulatorsa
Identifier | OV | Modulator | Disease setting | Status |
|---|---|---|---|---|
NCT02705196 | LOAd703 (AdV) | Gemcitabine Nab-paclitaxel | Pancreatic cancer | Phase I/II/Recruiting |
NCT05113290 | AdV | Sorafenib | HCC | Phase IV/Active, not recruiting |
NCT05070221 | rHSV2hGM-CSF (HSV) | Axitinib (RTKi) + anti-PD-1 mAb | Melanoma stage IV | Phase I/Not yet recruiting |
NCT03152318 | rQNestin34.5v.2 (HSV) | Cyclophosphamide | Recurrent malignant glioma | Phase I/Recruiting |
NCT03866525 | OH2 (HSV) | +/− irinotecan | Solid tumor/GI cancer | Phase I/II/Recruiting |
NCT02562755 | Pexa-Vec (VV) | Sorafenib (RTKi) | HCC | Phase III/Completed |
NCT03605719 | Pelareorep (Reovirus) | Carfilzomib | Recurrent plasma cell myeloma | Phase I/Active, not recruiting |
NCT03017820 | VSV-hIFN-NIS (VSV) | Ruxolitinib (JTKi)b (+/− Cyclophosphamide) | Multiple myeloma, Acute myeloid leukimia, T-cell lymphoma | Phase I/Recruiting |
NCT03120624 | VSV-hIFN-NIS (VSV) | Ruxolitinib (JTKi) | Endometrial cancer | Phase I/Recruiting |
NCT04665362 | M1-c6v1 (M1) | Apatinib (RTKi) Anti-PD-1 mAb | Advanced/metastatic HCC | Phase I/Not yet recruiting |
NCT01394939 | Pexa-Vec (VV) | +/− Irinotecan (Topoisomerase I inhibitor) | Metastatic, refractory colorectal carcinoma | Phase I/II /Completed |
NCT00450814 | MV-NIS (MV) | Cyclophosphamide | Recurrent or refractory multiple myeloma | Phase I/II /Completed |